Barnes & Noble (BKS) trimmed down its loss in the second quarter of 2019 with a year-over-year drop in sales. The bookseller’s loss stood at $27.4 million, or $0.38 per share compared to a loss of $30.1 million, or $0.41 per share in the prior year quarter. Revenue declined 2.5% to $771 million, while comp store sales decreased 1.4%.
Once the book-selling juggernaut Barnes & Noble announced last month that the board is exploring options after it has got inquiries from various firms to acquire the retailer. The potential parties that showed interest in taking over the company included its current Chairman Leonard Riggio.
“While we cannot predict the outcome of the holiday, we are putting our full effort behind our holiday plans, including launching a new ad campaign. We expect this to lead to continued sales improvement during the holiday period,” said Leonard Riggio.
For fiscal 2019, Barnes & Noble continues to expect EBITDA to be in a range of $175 million to $200 million, excluding unusual or non-recurring items.
Earlier in July, the company axed its CEO Demos Parneros, who didn’t even complete one year as the bookseller’s CEO. In August, Parneros filed a case against the company, mainly alleging its Chairman Riggio. Then, the company came out with the reasons for terminating Parneros and accused him of sexual harassment and violating other company policies.
The New York-based company’s shares closed down 2.31% at $6.76 on Monday and were down 2.5% when the market opened today. The stock dropped 1% in the year-to-date period, while declining 9% in the past 52-weeks.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with